OraQuick® HIV 1/2 Rapid Antibody Test

About OraSure Technologies

OraSure Technologies specializes in the development, manufacture, and distribution of rapid diagnostic tests and collection devices for infectious diseases, substance abuse, and other health conditions. Its core innovation lies in oral fluid (saliva) diagnostics, which offer a less invasive alternative to blood draws. The company has achieved significant commercial success with its OraQuick® rapid HIV test and played a major role in the COVID-19 pandemic response with its InteliSwab® rapid antigen test and molecular collection kits. OraSure operates as a publicly traded entity, focusing on expanding its infectious disease portfolio and leveraging its platform for new market opportunities.

Therapeutic Areas

Other Human Immunodeficiency Virus (HIV) infection Drugs